Contact:

Dr. Agnes P. Olszewski
Phone: (201) 647-3757

Email: dragnes@herborium.com

Herborium Group Announces Acquisition Strategy

Teaneck, New Jersey, May 17, 2007 Herborium Group, Inc. (HBRM.OB), a developer and marketer of novel botanical therapeutics®, including its successful Acne and Rosacea treatment (www.acnease.com), announced today that it has narrowed its acquisition targets to two companies engaged in developing and marketing proprietary, clinically tested Traditional Chinese Medicinal (‘TCM”) formulations.

Herborium’s business model takes advantage of the highly attractive botanical therapeutics market potential and present regulatory changes in the healthcare industry. These advantages provide for robust growth opportunities through acquiring controlling interest in one or more successful TCM companies in China.

"We are very serious about growing the company’s revenues, profitability and the leadership position in the sector. One way to accomplish this is through successful acquisitions of other entities that bring desirable value to Herborium." said Dr. Agnes P. Olszewski, President and CEO of Herborium. "One of the companies we most like to acquire currently enjoys high profit margins with revenues of approximately $5 million and a substantial growth potential. These are exciting times for our company." 

Herborium also announced that it was recently accepted as the first Western company as member of the Council for Globalization of TCM, a division of the Association for Advancement of Health and Medicine established by Chinese Ministry of Health in 1984. This membership offers Herborium a unique access to acquisition candidates in China with the best product profiles, and will assist with the evaluation and selection process.

Such acquisition opportunities are subject to the completion of due diligence and definitive agreements and there is no assurance that any of the transactions will be consummated.

This release and oral statements made from time to time by the Company's representatives concerning the same subject matter may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by the Company with the SEC, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.